# PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

> **NCT03283943** · PHASE1 · UNKNOWN · sponsor: **British Columbia Cancer Agency** · enrollment: 22 (estimated)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer

## Interventions

- **RADIATION:** Focal radiotherapy
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03283943
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-01
- **Primary completion:** 2020-12-16
- **Final completion:** 2020-12-16
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2018-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283943, "PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03283943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*